Elevated levels of established risk factors for thrombosis, in particular elevated levels of VWF and decreased levels of ADAMTS-13 which suggests endothelial activation, may be considered in the treatment of COVID-19. This evidence concerns the gene ADAMTS13 and COVID-19.